Evidence map›Paper›PMID 40983649›Full record

ArticleNature communications2025

Macrophage ferroptosis potentiates GCN2 deficiency induced pulmonary venous arterialization.

Jingyuan Zhang, Pei Mao, Tengfei Zhou, Bingqing Yue, Yaning Li, Yuanhua Qiu, Kejing Ying, Fudi Wang, Jingyu Chen, Jun Yang

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Interleukin-6 is critical in the development of pulmonary vascular disease inProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingyuan Zhang *Department of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0009-4924-8916
Pei Mao *Department of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0008-1116-4269
Tengfei Zhou *Department of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-1477-4798
Bingqing YueState Key Laboratory of Transvascular Implantation Devices of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-3268-2299
Yaning LiDepartment of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0009-0008-7558-7607
Yuanhua QiuDepartment of Pulmonary and Critical Care Medicine of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-2831-9182
Kejing YingDepartment of Pulmonary and Critical Care Medicine of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0001-9642-3929
Fudi WangDepartment of Public Health of Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0001-8730-0003
Jingyu ChenState Key Laboratory of Transvascular Implantation Devices of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jun YangDepartment of Physiology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. yang_jun@zju.edu.cn.ORCID http://orcid.org/0000-0001-9715-8100

Funding

China Postdoctoral Science Foundation 2022M712751Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2021YFA1100500Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2023YFC2507100Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2023YFC2507103National Natural Science Foundation of China (National Science Foundation of China) 81670054National Natural Science Foundation of China (National Science Foundation of China) 82100364National Natural Science Foundation of China (National Science Foundation of China) 82470431
6 · The paper itself

Abstract

Pulmonary veno-occlusive disease (PVOD) is a fatal disease characterized by the remodelling of pulmonary veins and haemosiderin accumulation in macrophages. Although (General Control Nonderepressible 2) GCN2 deficiency has been reported in PVOD patients, the underlying mechanism by which GCN2 deficiency affects the pulmonary venous cells and the surrounding cells, remains unclear. Here, we perform immunohistochemistry and scRNA-sequencing analyses to show that macrophages are the major population affected by GCN2 deficiency and ferroptosis pathway-related genes are upregulated in lung macrophages of PVOD patients. Treatment with the specific ferroptosis inhibitor ferrostatin-1 (Fer-1) reverses the changes in haemodynamic indices observed in Eif2ak4

Indexed as

FerroptosisMacrophagesPulmonary VeinsPulmonary Veno-Occlusive DiseaseAnimalsCyclohexylaminesDisease Models, AnimalEndothelial CellsFemaleHeme Oxygenase-1HumansIronMaleMiceMice, Inbred C57BLPhenylenediaminesCyclohexylaminesEIF2AK4 protein, humanferrostatin-1Heme Oxygenase-1IronPhenylenediaminesProtein Serine-Threonine Kinases

Identifiers

PMID40983649
PMCPMC12454641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.